Fibrotherapeutics, Inc.
Publicly observedCharleston, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Charleston | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Fibrotherapeutics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | JJ38AXUA8LD5 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant5 Sept 2026Publicly observed
NIH SBIR/STTR award: A Novel Water-Soluble, Orally-Active Peptide Therapeutic for Interstitial Lung Disease Derived from the Caveolin-1 Scaffolding Domain
USD 920,624.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
- Grant15 Feb 2023Publicly observed
NIH SBIR/STTR award: Novel Therapeutics for Heart Failure: Modified, Water-Soluble Caveolin-1 Scaffolding Domain Peptides with Improved Characteristics for Drug Development: Phase II
USD 1,917,034.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.